9 research outputs found
Factors associated with poor outcome (admission to ICU or death) among 48 MERS patients.
<p>Factors associated with poor outcome (admission to ICU or death) among 48 MERS patients.</p
Factors associated with fatal outcome in 48 MERS cases.
<p>Factors associated with fatal outcome in 48 MERS cases.</p
Factors associated with fatal outcome in 48 MERS cases.
<p>Factors associated with fatal outcome in 48 MERS cases.</p
Time from hospital admission to death.
<p>A: Comparing patients with MERS-CoV infection (red line) and those negative for MERS-CoV (black line) (p = 0.01). B: Comparing health care workers with MERS CoV (red dotted line; group1), non-HCW with MERS (red solid line; group 2) and patients without MERS-CoV infection (black solid line; group 3). Log rank test group 1 vs. group 2 p = 0.003; group 2 vs group 3 p = 0.45; group 1 vs group 3 p<0.001.</p
Comparison of laboratory parameters among three patient groups.
<p>Comparison of laboratory parameters among three patient groups.</p
Demographics of MERS positive HCW, MERS positive non-HCW and MERS negative cases.
<p>Demographics of MERS positive HCW, MERS positive non-HCW and MERS negative cases.</p
Time from hospital admission to death stratified by comorbid disease status among MERS positive cases.
<p>Survival analysis was carried out to ascertain impact of co-morbidities on survival in patients with MERS-CoV infection. Black line (group 1): No comorbid disease; Red line (group 2): Diabetes with or without other comorbidities; Green line (group 3): Any other comorbid disease without diabetes. Log rank test: group 1 vs group 2 p = 0.01; Group 1 vs. group 3 p = 0.54; group 2 vs. group 3 p = 0.01.</p
Comparison of clinical symptoms and co-morbidity status among the three patient groups.
<p>Comparison of clinical symptoms and co-morbidity status among the three patient groups.</p
Table_1_Molecular Typing of ST239-MRSA-III From Diverse Geographic Locations and the Evolution of the SCCmec III Element During Its Intercontinental Spread.PDF
<p>ST239-MRSA-III is probably the oldest truly pandemic MRSA strain, circulating in many countries since the 1970s. It is still frequently isolated in some parts of the world although it has been replaced by other MRSA strains in, e.g., most of Europe. Previous genotyping work (Harris et al., 2010; Castillo-RamÃrez et al., 2012) suggested a split in geographically defined clades. In the present study, a collection of 184 ST239-MRSA-III isolates, mainly from countries not covered by the previous studies were characterized using two DNA microarrays (i) targeting an extensive range of typing markers, virulence and resistance genes and (ii) a SCCmec subtyping array. Thirty additional isolates underwent whole-genome sequencing (WGS) and, together with published WGS data for 215 ST239-MRSA-III isolates, were analyzed using in-silico analysis for comparison with the microarray data and with special regard to variation within SCCmec elements. This permitted the assignment of isolates and sequences to 39 different SCCmec III subtypes, and to three major and several minor clades. One clade, characterized by the integration of a transposon into nsaB and by the loss of fnbB and splE was detected among isolates from Turkey, Romania and other Eastern European countries, Russia, Pakistan, and (mainly Northern) China. Another clade, harboring sasX/sesI is widespread in South-East Asia including China/Hong Kong, and surprisingly also in Trinidad & Tobago. A third, related, but sasX/sesI-negative clade occurs not only in Latin America but also in Russia and in the Middle East from where it apparently originated and from where it also was transferred to Ireland. Minor clades exist or existed in Western Europe and Greece, in Portugal, in Australia and New Zealand as well as in the Middle East. Isolates from countries where this strain is not epidemic (such as Germany) frequently are associated with foreign travel and/or hospitalization abroad. The wide dissemination of this strain and the fact that it was able to cause a hospital-borne pandemic that lasted nearly 50 years emphasizes the need for stringent infection prevention and control and admission screening.</p